Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo terminates inhaled fentanyl research pact

This article was originally published in Scrip

Executive Summary

Endo Pharmaceuticalshas terminated its fentanyl research collaboration with Alexza Pharmaceuticalsfollowing a strategic review. In 2007 the firms agreed to develop an inhaled fentanyl product for the treatment of breakthrough pain using Alexza’s Staccato technology in North America. The product, Staccato fentanyl (AZ-003/EN-3284), has completed Phase I clinical studies, and its rights will be returned to Alexza.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel